GlassScriptPhysician profile
Corneliu Ilea
NPI 1114573151
$1,602.61
in general payments reported to CMS, 2019-2025
22 companies · $913 in 2025
The $913 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2023: $398 · 2024: $189 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $354.35 | 2021-2025 | Imfinzi, Tagrisso, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $284.94 | 2023-2025 | Opdivo |
| Abbvie INC. | $195.81 | 2024-2025 | |
| Daiichi Sankyo INC. | $168.05 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Janssen Biotech, INC. | $85.48 | 2023-2025 | Erleada, Rybrevant |
| Merck Sharp & Dohme LLC | $56.39 | 2025 | Keytruda, Keytruda Qlex |
| Sobi, INC | $42.96 | 2025 | |
| Novocure INC. | $40.55 | 2025 | Optune Lua (Novottf-200t) |
| Blueprint Medicines Corporation | $39.67 | 2023 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $39.30 | 2023 | Ninlaro |
| Adc Therapeutics America, INC. | $35.11 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.76 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $29.51 | 2023 | Imbruvica |
| Aimmune Therapeutics, INC. | $29.10 | 2025 | Vowst |
| Genzyme Corporation | $28.64 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $25.00 | 2024 | Jakafi |
| Astellas Pharma US INC | $22.87 | 2025 | Vyloy |
| Pharmacosmos Therapeutics INC. | $22.08 | 2025 | Monoferric |
| Beone Medicines USA, INC. | $20.19 | 2025 | Tevimbra |
| Eisai INC. | $19.49 | 2025 | |
| Janssen Scientific Affairs, LLC | $18.03 | 2024 | Carvykti, Darzalex, Tecvayli |
| Emd Serono, INC. | $15.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corneliu Ilea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.